Bengaluru: AstraZeneca is reportedly in discussions with Summit Therapeutics to license an experimental lung cancer drug in a ...

He clarified that his use of the term “hastily” was in reference to the emergency rollout timelines that global health ...

AstraZeneca’s Imfinzi receives European approval to treat patients with resectable muscle-invasive bladder cancer: Cambridge, UK Saturday, July 5, 2025, 09:00 Hrs [IST] AstraZen ...

Experts and agencies reject any link between COVID-19 vaccines and sudden cardiac deaths, citing studies showing no causal ...

It comes amid reports that the drugs maker is considering moving its listing from the UK to the US in what would be a hammer ...

Both well-established and small, clinical-stage pharma companies are investing heavily to be able to someday compete with ...

AstraZeneca PLC logged a -2.4% change during today's morning session, and is now trading at a price of $69.45 per share. The ...

The Cambridge, England-based pharmaceutical company said Imfinzi has been approved in the EU for treatments in adults with resectable muscle-invasive bladder cancer. The approval is for the use of ...

ASTRAZENECA is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as $15 billion, Bloomberg News reported on Thursday, citing people familiar with ...

AstraZeneca PLC closed 22.80% short of its 52-week high of £133.88, which the company reached on September 3rd.

By integrating foundation models into its R&D pipeline, AstraZeneca seeks to enable data-driven discovery methods.

The approval comes amid speculation that the big pharma company may switch its UK stock market listing to the US.